{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:35:01Z","timestamp":1773455701785,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,5,4]],"date-time":"2019-05-04T00:00:00Z","timestamp":1556928000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s10147-019-01456-4","type":"journal-article","created":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T13:26:47Z","timestamp":1557149207000},"page":"1105-1110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Clinical background and outcomes of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancers in Japan"],"prefix":"10.1007","volume":"24","author":[{"given":"Hidetaka","family":"Nomura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seigo","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,4]]},"reference":[{"key":"1456_CR1","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317:2102\u20132416","journal-title":"JAMA"},{"key":"1456_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"MC King","year":"2003","unstructured":"King MC, Marks JH, Mandell JB et al (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643\u2013646","journal-title":"Science"},{"key":"1456_CR3","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1056\/NEJM199705153362001","volume":"336","author":"JP Struewing","year":"1997","unstructured":"Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401\u20131408","journal-title":"N Engl J Med"},{"key":"1456_CR4","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329\u20131333","journal-title":"J Clin Oncol"},{"key":"1456_CR5","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105:812\u2013822","journal-title":"J Natl Cancer Inst"},{"key":"1456_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10689-007-9144-x","volume":"7","author":"KH Lu","year":"2008","unstructured":"Lu KH (2008) Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis. Fam Cancer 7:53\u201358","journal-title":"Fam Cancer"},{"key":"1456_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ygyno.2005.08.038","volume":"100","author":"RI Olivier","year":"2006","unstructured":"Olivier RI, Lubsen-Brandsma MA, Verhoef S et al (2006) CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 100:20\u201326","journal-title":"Gynecol Oncol"},{"key":"1456_CR8","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1200\/JCO.2005.05.097","volume":"23","author":"D Stirling","year":"2005","unstructured":"Stirling D, Evans DG, Pichent G et al (2005) Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international federation of gynecology and obstetrics system. J Clin Oncol 23:5588\u20135596","journal-title":"J Clin Oncol"},{"key":"1456_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/annonc\/mdt311","volume":"24","author":"A Gadducci","year":"2013","unstructured":"Gadducci A, Sergiampietri C, Tana R (2013) Alternatives to risk-reducing surgery for ovarian cancer. Ann Oncol Suppl 24:47\u201353","journal-title":"Ann Oncol Suppl"},{"key":"1456_CR10","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1097\/AOG.0b013e318238d030","volume":"118","author":"JR van Nagell","year":"2011","unstructured":"van Nagell JR, Miller RW Jr, DeSimone CP et al (2011) Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet Gynecol 118:1212\u20131221","journal-title":"Obstet Gynecol"},{"key":"1456_CR11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1001\/jama.2017.21421","volume":"319","author":"JT Henderson","year":"2018","unstructured":"Henderson JT, Webber EM, Sawaya GF (2018) Screening for ovarian cancer: updated evidence report and systematic review for the US preventive services Task Force. JAMA 319:595\u2013606","journal-title":"JAMA"},{"key":"1456_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek SM, Friebel TM, Singer CE et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carrier with cancer risk and mortality. JAMA 304:967\u2013975","journal-title":"JAMA"},{"key":"1456_CR13","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/bjc.2011.573","volume":"106","author":"L Sidon","year":"2012","unstructured":"Sidon L, Ingham S, Clancy T et al (2012) Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women. Br J Cancer 106:775\u2013779","journal-title":"Br J Cancer"},{"key":"1456_CR14","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/ejhg.2010.241","volume":"19","author":"C Julian-Reynier","year":"2011","unstructured":"Julian-Reynier C, Mancini J, Mouret-Fourme E et al (2011) Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1\/2 mutations. Eur J Hum Genet 19:500\u2013506","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"1456_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00404-010-1476-3","volume":"283","author":"K Rhiem","year":"2011","unstructured":"Rhiem K, Foth D, Wappenschmidt B et al (2011) Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. Arch Gynecol Obstet 283(3):623\u2013627","journal-title":"Arch Gynecol Obstet"},{"key":"1456_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00432-015-2051-x","volume":"142","author":"SI Kim","year":"2016","unstructured":"Kim SI, Lim MC, Lee DO et al (2016) Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea. J Cancer Res Clin Oncol 142:333\u2013340","journal-title":"J Cancer Res Clin Oncol"},{"key":"1456_CR17","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1056\/NEJMoa012158","volume":"346","author":"TR Rebbeck","year":"2002","unstructured":"Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616\u20131622","journal-title":"N Engl J Med"},{"key":"1456_CR18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.maturitas.2014.12.009","volume":"80","author":"CM Van Driel","year":"2015","unstructured":"Van Driel CM, deBock GH, Arts HJ et al (2015) Stopping ovarian cancer screening in BRCA1\/2 mutation carriers: effects on risk management decisions and outcome of risk-reducing salpingo-oophorectomy specimens. Maturitas 80:318\u2013322","journal-title":"Maturitas"},{"key":"1456_CR19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.maturitas.2010.03.018","volume":"66","author":"MJ Kenkhuis","year":"2010","unstructured":"Kenkhuis MJ, deBock GH, Elferink PO et al (2010) Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1\/2 mutation carriers. Maturitas 66:310\u2013314","journal-title":"Maturitas"},{"key":"1456_CR20","unstructured":"Kim HL, Puymon MR, Qin M et al (2013) NCCN clinical practice guidelines in oncology. \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf\n                    \n                  . Accessed Jun 2018"},{"key":"1456_CR21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1200\/JCO.2006.07.4922","volume":"20","author":"JB Madalinska","year":"2007","unstructured":"Madalinska JB, van Beurden M, Bleiker EM et al (2007) Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1\/2 mutation carriers. J Clin Oncol 20:301\u2013307","journal-title":"J Clin Oncol"},{"key":"1456_CR22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ygyno.2017.02.008","volume":"145","author":"PL Mai","year":"2017","unstructured":"Mai PL, Piedmonte M, Han PK et al (2017) Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: an NRG Oncology\/Gynecologic Oncology Group study. Gynecol Oncol 145:122\u2013129","journal-title":"Gynecol Oncol"},{"key":"1456_CR23","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/pon.2041","volume":"22","author":"A Finch","year":"2013","unstructured":"Finch A, Metcalfe KA, Chiang J et al (2013) The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psychooncology 22:212\u2013219","journal-title":"Psychooncology"},{"key":"1456_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s10038-017-0355-1","volume":"63","author":"M Arai","year":"2017","unstructured":"Arai M, Yokoyama S, Watanabe C et al (2017) Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan. J Hum Genet 63:447\u2013457","journal-title":"J Hum Genet"},{"key":"1456_CR25","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S1470-2045(06)70869-5","volume":"7","author":"WA Rocca","year":"2006","unstructured":"Rocca WA, Grossardt BR, de Andrade M et al (2006) Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 7:821\u2013828","journal-title":"Lancet Oncol"},{"key":"1456_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.maturitas.2011.08.001","volume":"70","author":"A Finch","year":"2011","unstructured":"Finch A, Narod SA (2011) Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: a review. Maturitas 70:261\u2013265","journal-title":"Maturitas"},{"key":"1456_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/jjco\/hyv190","volume":"46","author":"M Shigehiro","year":"2016","unstructured":"Shigehiro M, Kita M, Takeuchi S et al (2016) Study on the psychosocial aspects of risk-reducing salpingo-oophorectomy (RRSO) in BRCA1\/2 mutation carriers in Japan: a preliminary report. Jpn J Clin Oncol 46:254\u2013259","journal-title":"Jpn J Clin Oncol"},{"key":"1456_CR28","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.3802\/jgo.2017.28.e3","volume":"28","author":"YJ Lee","year":"2017","unstructured":"Lee YJ, Lee SW, Kim KR et al (2017) Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers. J Gynecol Oncol 28:e3","journal-title":"J Gynecol Oncol"},{"key":"1456_CR29","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1503523","volume":"374","author":"LC Hartmann","year":"2016","unstructured":"Hartmann LC, Lindor NM (2016) The role of risk-reducing surgery in hereditary breast and ovarian cancer. N Engl J Med 374:454\u2013468","journal-title":"N Engl J Med"},{"key":"1456_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/cge.12130","volume":"85","author":"T Pal","year":"2014","unstructured":"Pal T, Lee JH, Besharat A et al (2014) Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers. Clin Genet 85:49\u201353","journal-title":"Clin Genet"},{"key":"1456_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/GIM.0b013e318163487d","volume":"10","author":"AR Bradbury","year":"2008","unstructured":"Bradbury AR, Ibe CN, Dignam JJ et al (2008) Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med 10:161\u2013166","journal-title":"Genet Med"},{"key":"1456_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ygyno.2016.07.104","volume":"143","author":"MG Harmsen","year":"2016","unstructured":"Harmsen MG, Arts-de Jong M, Horstik K et al (2016) Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1\/2 mutation carriers: a single-center experience. Gynecol Oncol 143:113\u2013119","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01456-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-019-01456-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01456-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T23:25:57Z","timestamp":1588461957000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-019-01456-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,4]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1456"],"URL":"https:\/\/doi.org\/10.1007\/s10147-019-01456-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,4]]},"assertion":[{"value":"22 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Seigo Nakamura received an honoraria for a seminar presentation from AstraZeneca. Dr. Takayuki Enomoto received an honoraria for lecture fees from Chugai Pharm. Dr. Masayuki Sekine received an honoraria for lecture fees from AstraZeneca. The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}